Pluri Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluri Inc. on December 9, 2025, covering events occurring on December 8, 2025. The Company, incorporated in Nevada and headquartered in Haifa, Israel, operates in the advanced technology sector. The filing primarily addresses a private placement offering, changes in board leadership, and executive compensation adjustments.
Key Financial Metrics and Capital Structure
The filing details a private placement offering with the following financial parameters:
- Expected Gross Proceeds: Approximately $2.5 million.
- Securities Issued: 625,000 Common Shares and warrants to purchase up to 625,000 Common Shares.
- Purchase Price: $4.00 per combined Common Share and Common Warrant.
- Warrant Terms: Exercise price of $4.25 per share; exercisable immediately until June 30, 2026.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels for the reporting period.
Material Changes and Corporate Actions
Significant corporate actions reported include:
- Private Placement: Entry into a Securities Purchase Agreement with Chutzpah Holdings LP, beneficially owned by existing shareholder and director Mr. Alexandre Weinstein.
- Board Leadership Changes: Effective December 4, 2025, Mr. Alexandre Weinstein was appointed Chairman of the Board, and Mr. Zami Aberman was appointed Vice Chairman of the Board.
- Executive Compensation: On December 4, 2025, the Board granted 10,248 Restricted Stock Units (RSUs) to the CEO and CFO and 2,885 RSUs to Board members. These grants replace cash compensation to support cost-management initiatives and vest over three months.
- Consultancy Termination: Mr. Aberman's consultancy agreement will terminate effective January 4, 2026.
Outlook, Risks, and Contingencies
Management expects the offering to close on or about December 15, 2025, subject to customary closing conditions. The filing includes a Safe Harbor Statement highlighting significant risks that could cause actual results to differ from forward-looking statements, including:
- Failure to meet closing conditions for the offering.
- Delays or obstacles in clinical trials and regulatory approvals.
- Technology validation issues and scientific difficulties.
- Inability to retain key employees or attract new talent.
- Competitive pressures and pricing challenges.
Investor Verification Checklist
- Verify the closing of the $2.5 million private placement on or before December 15, 2025.
- Confirm the final terms of the warrants, specifically the 35% beneficial ownership limitation and anti-dilution provisions.
- Monitor the impact of the shift from cash to equity-based compensation on the Company's cash burn rate.
- Review the termination of Mr. Aberman's consultancy agreement and its effect on ongoing operations.
- Assess the Company's progress on clinical trials and regulatory approvals as noted in the risk factors.